Literature DB >> 16399424

Morbidity and mortality are not increased after induction chemoradiotherapy followed by esophagectomy in patients with esophageal cancer.

Adam C Berger1, Walter J Scott, Gary Freedman, Andre Konski, Louis Weiner, Jonathan D Cheng, Melvyn Goldberg.   

Abstract

Attempts to improve survival of patients with esophageal cancer have been made using induction chemoradiotherapy (CRT) followed by surgery. This approach may be associated with higher complication rates. A large single-center experience was reviewed to determine whether induction CRT was associated with increased morbidity and mortality among 179 patients undergoing esophagectomy between January 1994 and December 2002. Morbidity was recorded as any complication requiring additional intervention. Mortality was defined as patient death within the first 30 postoperative days or death during the initial hospitalization. In total, 131 patients underwent induction CRT followed by surgery. The most common operation was an Ivor-Lewis esophagogastrectomy (60%). Median survival of the entire group was 33 months and 5-year survival was 26%. Perioperative mortality was 5% and did not differ between induction (4.6%) and non-induction (6.3%) groups. The overall complication rate was 57%, reflecting a very liberal definition of postoperative complications. There were no differences between the two groups in terms of such major complications as anastomotic leak, pneumonia, acute respiratory distress syndrome, respiratory failure, chylothorax, atrial arrhythmia, and wound infections. There were only two complications that occurred more frequently in the induction group--venous thrombosis (8.4% v 0%) and vocal cord paresis (7.6% v 2.1%). The median hospital stay was similar in patients who had complications versus those who did not (12 v 13 days) and in patients who underwent induction CRT versus those that did not (12 days v 13.5 days). Esophagectomy can be performed safely with low mortality and acceptable morbidity following neoadjuvant chemotherapy and radiation with no increase in hospital stay for patients with complications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16399424     DOI: 10.1053/j.seminoncol.2005.04.017

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  9 in total

1.  Neoadjuvant chemotherapy for locally advanced gastric cancer: With or without radiation.

Authors:  Ai-Wen Wu; Jia-Fu Ji
Journal:  World J Gastrointest Surg       Date:  2012-02-27

2.  Mortality rate associated with 56 consecutive esophagectomies performed at a "low-volume" hospital: is procedure volume as important as we are trying to make it?

Authors:  Brian Santin; Aaron Kulwicki; Phillip Price
Journal:  J Gastrointest Surg       Date:  2008-06-10       Impact factor: 3.452

Review 3.  Update on staging and surgical treatment options for esophageal cancer.

Authors:  Donald E Low
Journal:  J Gastrointest Surg       Date:  2011-05       Impact factor: 3.452

4.  The Effect of Neoadjuvant Therapy on Early Complications of Esophageal Cancer Surgery.

Authors:  Mohammadtaghi Rajabi Mashhadi; Reza Bagheri; Abbas Abdollahi; Mohammad Javad Ghamari; Soudabeh Shahidsales; Maryam Salehi; Reza Shahkaram; Mohamad Reza Majidi; Shima Sheibani
Journal:  Iran J Otorhinolaryngol       Date:  2015-07

5.  Bidirectional risk between venous thromboembolism and cancer in East Asian patients: synthesis of evidence from recent population-based epidemiological studies.

Authors:  Victor C Kok
Journal:  Cancer Manag Res       Date:  2017-12-05       Impact factor: 3.989

Review 6.  Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival.

Authors:  K E O'Sullivan; E T Hurley; J P Hurley
Journal:  Gastroenterol Res Pract       Date:  2015-07-13       Impact factor: 2.260

7.  A clinical trial of neoadjuvant concurrent chemoradiotherapy followed by resection for esophageal carcinoma.

Authors:  Kazem Anvari; Seyed Amir Aledavood; Mehdi Seilanian Toussi; Mohammad Naser Forghani; Samira Mohtashami; Mohammad Taghi Rajabi; Fatemeh Homaee Shandiz; Fatemeh Nosrati; Gholamhossein Nowferesti; Roham Salek
Journal:  J Res Med Sci       Date:  2015-08       Impact factor: 1.852

8.  Neoadjuvant Chemoradiotherapy Improving Survival Outcomes for Esophageal Carcinoma: An Updated Meta-analysis.

Authors:  Dong-Bin Wang; Zhong-Yi Sun; Li-Min Deng; De-Qing Zhu; Hong-Gang Xia; Peng-Zhi Zhu
Journal:  Chin Med J (Engl)       Date:  2016-12-20       Impact factor: 2.628

Review 9.  History and current situation of neoadjuvant treatment for locally advanced esophageal cancer.

Authors:  Junyi Li; Shaohua Ma
Journal:  Thorac Cancer       Date:  2021-07-13       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.